3.81
-0.43(-10.14%)
Currency In USD
Previous Close | 4.24 |
Open | 4.2 |
Day High | 4.29 |
Day Low | 3.81 |
52-Week High | 100.8 |
52-Week Low | 2.77 |
Volume | 83,465 |
Average Volume | 1.59M |
Market Cap | 8.2M |
PE | -0.23 |
EPS | -16.41 |
Moving Average 50 Days | 4.43 |
Moving Average 200 Days | 10.86 |
Change | -0.43 |
If you invested $1000 in HCW Biologics Inc. (HCWB) since IPO date, it would be worth $604.76 as of September 08, 2025 at a share price of $3.81. Whereas If you bought $1000 worth of HCW Biologics Inc. (HCWB) shares 3 years ago, it would be worth $35.81 as of September 08, 2025 at a share price of $3.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
GlobeNewswire Inc.
Aug 25, 2025 12:00 PM GMT
Company’s pembrolizumab-based immune checkpoint inhibitor exhibited success against solid tumors in IND-enabling studies by simultaneously activating immune cells and promoting their infiltration into solid tumors Presentation at Nova Southeastern Un
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
GlobeNewswire Inc.
Jun 27, 2025 11:45 AM GMT
Tetra-functional T-cell engagers activate T cells and simultaneously reduce immunosuppression, with potent and antigen-specific anti-pancreatic cancer activities at dose levels that are well tolerated Presentation at the Phoenix Best Science Series b
HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements
GlobeNewswire Inc.
Jun 26, 2025 11:55 AM GMT
Company in full compliance for continued listingMIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developin